NDA 022343 · Aurobindo Pharma LTD
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
Efavirenz, Lamivudine, Tenofovir Disoproxil Fumarate · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 15, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Aug 15, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
432
116 Phase 3, 6 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE · EFAVIRENZ 600MG; LAMIVUDINE 300MG; TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Efavirenz" as an intervention, any sponsor and status, largest first.
- Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV IncidencePivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT01509508 · 28,153 participants · Start Mar 2012 · Primary completion Jun 2016
Drug: Immediate ARV treatment initiation with TDF/FTC/EFV · For: HIV Infection
Sites: Hlabisa, South Africa
- Preventing Sexual Transmission of HIV With Anti-HIV DrugsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00074581 · 3,526 participants · Start Feb 2005 · Primary completion May 2015
Drug: Atazanavir; Didanosine and 8 more · For: HIV Infections
Sites: Boston, Massachusetts; Gaborone, Botswana; Nova Iguaçu, Brazil · 17 sites in all
- Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive AdultsPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00118898 · 1,864 participants · Start Sep 2005 · Primary completion Nov 2009
Drug: Abacavir/Lamivudine; Atazanavir and 5 more · For: HIV Infections
Sites: Los Angeles, California; Palo Alto, California; San Diego, California · 52 sites in all
- Antiretroviral Therapy for Advanced HIV Disease in South AfricaPivotal-lookingCompleted
National Institutes of Health Clinical Center (CC)NIH
NCT00342355 · 1,771 participants · Start Jan 2004 · Primary completion Mar 2008
Drug: Zidovudine; Stavudine and 4 more · For: HIV
Sites: Centurion, South Africa; Eastaern Cape, South Africa; Free State, South Africa · 7 sites in all
- A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000922 · 1,710 participants · Primary completion Jan 2003
Drug: Indinavir sulfate; Abacavir sulfate and 6 more · For: HIV Infections
Sites: San Francisco, California; Denver, Colorado; New Haven, Connecticut · 17 sites in all
- Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited SettingsPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00084136 · 1,571 participants · Start May 2005 · Primary completion May 2010
Drug: Atazanavir; Didanosine (enteric-coated) and 4 more · For: HIV Infections
Sites: Los Angeles, California; Torrance, California; Denver, Colorado · 42 sites in all
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01815736 · 1,443 participants · Start Mar 27, 2013 · Primary completion Mar 16, 2015
Drug: E/C/F/TAF; E/C/F/TDF and 5 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 167 sites in all
- Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in AfricaPivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT02028676 · 1,206 participants · Start Mar 2007 · Primary completion Mar 2012
Drug: Arm A: ABC+3TC+NNRTI; Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance and 4 more · For: Human Immunodeficiency Virus
Sites: Entebbe, Uganda; Kampala, Uganda; Mulago, Uganda · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of doravirine in treatment-naive HIV-1-infected adults: a systematic review and meta-analysis.
Afify MA, Ahmed IGG, Alkahtani TA, et al. · Environ Sci Pollut Res Int 2021 · Meta-Analysis, Systematic Review
- Does antiretroviral therapy cause congenital malformations? A systematic review and meta-analysis.
Alemu FM, Yalew AW · Epidemiol Health 2021 · Meta-Analysis, Systematic Review
- Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis.
Chanhom N, Sonjan J, Inchai J, et al. · Sci Rep 2024 · Meta-Analysis, Systematic Review
- Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Pettit AC, Phillips PPJ, Kurbatova E, et al. · Clin Infect Dis 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
Kanters S, Vitoria M, Doherty M, et al. · Lancet HIV 2016 · Comparative Study, Systematic Review
- 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Patel DA, Snedecor SJ, Tang WY, et al. · PLoS One 2014 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Aurobindo Pharma LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.